Lentiviral vector for a University of Edinburgh gene therapy trial
- University of Edinburgh
- Scotland
- Competitive procedure with negotiation, 1 bid
The University of Edinburgh bought a high titre lentiviral vector, made to GMP standard, from Indiana University for a phase I/II gene therapy trial. The therapy modifies a patient's own CD34+ stem cells to treat a rare genetic disease that brings on dementia in children.
Indiana University must produce a 30 litre unconcentrated harvest from 293T cells and concentrate it by about 100 to 200 times. Quality control follows FDA rules, and the first delivery goes straight to the University of California, Los Angeles.
The university estimated the work at £900,000. One bid came in, and the award was £586,904. The contract runs for a year, with options to buy more deliveries over a further two.
- What
- Aseptic compounding, specials and contract pharmaceutical manufacturing
- 1 of 2 lots awarded
- Supplier
- Indiana University
- Value
- £586,904
- Across 1 lots
- How it was bought
- Competitive procedure with negotiation
- 1 bid
- Dates and next
- 7 Nov 2025